Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

AMO is a short acting complex I blocker that blocks mitochondrial complex I between flavoprotein and ubiquitin, and its blocking effect can be rapidly reversed. Our study is to explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Inclusion Criteria:

• Age range: 18-65 years old, undergo elective cardiac surgery with extracorporeal circulation.
• ASA II-III;
• surgical duration is 3-6 hours;
• Sign the informed consent form

Exclusion Criteria:

• BMI less than 18 kg/m2 or greater than 30 kg/m2;
• Individuals with a history or potential history of drug abuse or alcohol dependence;
• Preoperative use of sedatives or analgesics;
• Individuals with severe liver and kidney dysfunction;
• Individuals who are allergic or potentially allergic to barbiturates;
• Patients with coagulation dysfunction, endocrine disorders, or other conditions that affect hemodynamic status;
• Participated in other clinical studies in the past 3 months;
• The researchers believe that participants who are not suitable to participate in this study.